December 14, 201700:18:12

Novel Technology Enables Encapsulated Cell Therapies Without Triggering Fibrosis

Dr. Paul Wotton, CEO, talks about Sigilon Therapeutics’ discovery platform. The platform combines cell engineering and biocompatible Afibromer™ technology to enable cell therapeutics that do not trigger fibrosis.

No transcript available.